FDA Approves New HIV Med

Selzentry will become available next month. Pfizer plans on marketing the drug as Celsentri in other parts of the world. "Cell sentry", get it? As I mentioned in February, Selzentry must be taken twice a day, unlike many current HIV meds.Selzentry is the first in a class of drugs known as CCR5 antagonists, which block the CCR5 co-receptor, the virus' predominant entry route into T-cells. Selzentry stops the R5 virus on the outside surface of the cells before it enters, rather than fighting the virus inside as do all other classes of oral HIV medicines.